Go to page
 

Bibliographic Metadata

Title
Anogenital Human Papillomavirus Prevalence is Unaffected by Therapeutic Tumour Necrosis Factor-alpha Inhibition
AuthorHandisurya, Alessandra ; Lazar, Stefanie ; Papay, Pavol ; Primas, Christian ; Haitel, Andrea ; Horvat, Reinhard ; Tanew, Adrian ; Vogelsang, Harald
Published in
Acta Dermato-Venereologica, Uppsla, 2016, Vol. 96, Issue 4, page 494-498
PublishedUppsla : Society for the Publication of Acta Dermato-Venereologica, 2016
LanguageEnglish
Document typeJournal Article
Keywords (EN)human papillomavirus (HPV) / tumour necrosis factor-alpha / psoriasis / inflammatory bowel dis- ease / anogenital infection / HPV seroprevalence
ISSN0001-5555
URNurn:nbn:at:at-ubmuw:3-95 Persistent Identifier (URN)
DOI10.2340/00015555-2298 
Restriction-Information
 The work is publicly available
Files
Anogenital Human Papillomavirus Prevalence is Unaffected by Therapeutic Tumour Necrosis Factor-alpha Inhibition [0.29 mb]
Links
Reference
Classification
Abstract (English)

Patients receiving tumour necrosis factor alpha (TNF-) inhibitors are at increased risk of exacerbation of (myco-)bacterial and some viral infections. However, in- formation on anogenital human papillomavirus (HPV) infection in these patients is sparse or conflicting. In this study 222 patients with psoriasis or inflammatory bowel disease (IBD), who received either anti-TNF- inhibitors or alternatives (purine-, folic acid analogues, photothe- rapy, fumaric ester, mesalazine) continuously for at least 6 months, were evaluated for the presence of anogeni- tal HPV-induced lesions, mucosal HPV DNA, and sero- logical status of mucosal low-risk HPV6 and high-risk HPV16/HPV18. Hallmarks of anogenital HPV infection were more frequently detected in patients with psoriasis than in those with IBD. HPV-induced lesions, viral DNA, and seroprevalence were not elevated in participants with psoriasis or IBD, who received TNF- inhibitors for a mean duration of 31.4 months (range 696 months) compared with recipients of alternative or no treatment. TNF- blockade for a mean period of 31.4 months does not increase detectable anogenital HPV infection or dis- ease.

Stats
The PDF-Document has been downloaded 2 times.
License
CC-BY-NC-License (4.0)Creative Commons Attribution - NonCommercial 4.0 International License